What was the primary driver of Boston Scientific's revenue growth in this quarter?

The primary driver of revenue growth was the strong performance of the TAXUS drug-eluting coronary stent system, particularly its launch and sales in the U.S. market, which commenced in the first quarter of 2004.

How did recent acquisitions impact the company's financial performance?

The acquisitions of Advanced Bionics Corporation and Precision Vascular Systems, Inc. in 2004 expanded the company's technology portfolio and are expected to contribute to future growth. The acquisition of Advanced Bionics, in particular, added implantable microelectronic technologies to their offerings. These acquisitions also resulted in significant charges for purchased research and development, impacting net income.

What is the company's outlook regarding the coronary stent market and competition?

Boston Scientific anticipates continued strong growth in the coronary stent market, projecting it to approach $4.7 billion in 2004 and $5 billion in 2005. However, they acknowledge increasing competition and expect market share and pricing pressure as new drug-eluting stents enter the market. The company is focused on maintaining and expanding its market leadership through continued R&D and strategic investments.

Were there any significant product recalls or issues that affected the financials?

Yes, the company announced a voluntary recall of certain TAXUS Express(2) and Express(2) coronary stent systems due to a balloon non-deflation issue. This resulted in an inventory write-down of $43 million and impacted gross profit margins. The company has implemented corrective actions and is working with the FDA.

BSX 10-Q Quarterly Report Q2 FY2004 — Revenue, Net Income, EPS

Summary

Boston Scientific Corporation reported strong financial performance for the quarter ended June 30, 2004, driven by significant sales growth in its cardiovascular segment, particularly the TAXUS drug-eluting stent system. Net sales increased by 71% year-over-year, reaching $1.46 billion, while net income more than doubled to $313 million. This growth was bolstered by successful acquisitions, notably Advanced Bionics Corporation, which expanded the company's technological portfolio. The company's strategic focus on high-margin products and expansion into new markets is yielding positive results. Despite facing increased competition and ongoing litigation, Boston Scientific demonstrated robust operational execution. Investors should note the significant investments in research and development and potential future acquisitions, which signal a continued commitment to innovation and growth. The company also addressed inventory write-downs related to a product recall, which had a moderate impact on gross profit margins but did not derail the overall positive financial trajectory.

Key Highlights

1Net sales surged by 71% to $1.46 billion for the three months ended June 30, 2004, compared to the prior year period, primarily driven by the TAXUS drug-eluting stent system.
2Net income for the quarter more than doubled, reaching $313 million ($0.36 per diluted share), up from $114 million ($0.13 per diluted share) in the prior year.
3Acquisitions of Advanced Bionics Corporation and Precision Vascular Systems, Inc. in 2004 significantly expanded the company's product offerings and technological capabilities.
4Gross profit margin improved to 75.1% from 72.5% in the prior year, attributed to a favorable product mix shifting towards higher-margin drug-eluting stents.
5Operating expenses as a percentage of net sales decreased due to revenue growth outpacing SG&A spending increases.
6The company experienced an inventory write-down of $43 million related to a recall of certain coronary stent systems, impacting gross profit by approximately 300 basis points.
7Cash provided by operating activities increased significantly to $574 million for the six months ended June 30, 2004, compared to $354 million in the same period last year.

BOSTON SCIENTIFIC CORP Quarterly Report for Q2 Ended Jun 30, 2004

Summary

Key Highlights

Frequently Asked Questions